Allucent (India) Private Limited - Due diligence report

A 360° intelligence report on Pharm-Olam International: trust score, financial health, credit view, compliance, directors, growth and distre…

2002-11-27 Bangalore South, Karnataka Active Unlisted Active Compliant
Share
A( Allucent (India) Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pharm-Olam International — 360° Intelligence Report

Generated from MCA filings & public records
82/100
Trust Score
Low Risk

Pharm-Olam International is assessed as Low Risk with a Trust Score of 82/100. Pharm-Olam International is an active private limited indian non-government company incorporated in 2002, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Allucent (India) Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
40/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 40/100
NameDIN / PANDesignationAppointedTenureDIN status
SIVAKUMAR SUBRAMANIAN 01234567 Director 01/04/2018 6 yrs Approved
Howard Richard Brand 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • SIVAKUMAR SUBRAMANIAN has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Allucent (uk) Limited
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Allucent (uk) Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 23+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence84/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment90/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view90/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 6 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
29 Sep 2025
Director appointed
Howard Richard Brand (Additional Director)
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
28 Dec 2023
Director ceased
SIVAKUMAR SUBRAMANIAN
28 Sep 2023
Director ceased
SIVAKUMAR SUBRAMANIAN
31 Mar 2023
Share transfer (FY 2023)
1.00000000 shares to Sivakumar Subramanian
21 Feb 2023
Director appointed
SIVAKUMAR SUBRAMANIAN (Director)
05 Oct 2022
Director ceased
NATALIE KAY GASSEN
30 Sep 2022
Director ceased
CHRISTOPHER SCOTT BRENNAN
08 Jan 2020
Director ceased
DAVID LAWRENCE GRANGE
07 Dec 2017
Director ceased
ZEV MOSHE MUNK
Director ceased
SUSAN MUNK
31 Mar 2017
Share transfer (FY 2017)
1.00000000 shares to Tanjore Thanuja Naidu
01 Feb 2016
Director ceased
THANUJA NAIDU TANJORE VENKATAKRISHNA
30 Jun 2009
Director ceased
PAUL RICHARD HUNT
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); review board churn before relying on management continuity.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Fabtech Consulting Engineers Private Limited U74210MH2006PTC160139 Thane, Maharashtra, India
Infosage Systems (India) Private Limited U72200TG2004PTC044618 Hyderabad, Telangana, India
Isaac Luxe U93020DL2021PTC381443 Delhi, Delhi, India
Puthur Infotech U30007KA2006PTC041176 Bangalore, Karnataka, India
Motiprabha U45200DL2008PTC180398 Nehru Place, Delhi, India
Shinwa (India) Engineering & Trading Private Limited U29268KA2008PTC047055 Bangalore, Karnataka, India
Leegality U74999HR2016PTC066380 Gurugram, Haryana, India
Alethia Infotel Private Limited U72900DL2012PTC239677 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pharm-Olam International before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pharm-Olam International: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Pharm-Olam International - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Pharm-Olam International pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Pharm-Olam International - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pharm-Olam International an active company?

Pharm-Olam International has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Pharm-Olam International financially healthy?

Pharm-Olam International has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Pharm-Olam International?

Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pharm-Olam International?

The ultimate holding entity is Allucent (uk) Limited. 2 active director(s) are on record.

Does Pharm-Olam International have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Pharm-Olam International up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Pharm-Olam International?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.